In the dynamic landscape of pharmaceutical research and development, the availability of high-quality intermediates is paramount. NINGBO INNO PHARMCHEM CO.,LTD. recognizes the crucial role that specialized chemical compounds play in driving innovation. Among these, 2,3,5-Trimethylpyridine N-Oxide, identified by its CAS number 74409-42-0, stands out as a key building block. This compound is particularly important for its application in the preparation of Omeprazole metabolites, a critical area for understanding drug efficacy and metabolism.

The molecular formula C8H11NO encapsulates a structure that, with its specific methylation pattern and N-oxide functionality, offers unique reactivity for organic chemists. The physical properties of 2,3,5-Trimethylpyridine N-Oxide, such as its off-white to light brown solid form and solubility in common solvents like methanol and chloroform, make it amenable to various laboratory procedures. Its melting point of 40-41 °C and a boiling point of 95-98 °C at low pressure provide important parameters for process control.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing researchers and manufacturers with reliable access to such essential intermediates. Our focus on purity and consistent quality ensures that the chemical intermediate CAS 74409-42-0 can be effectively utilized in complex synthesis projects without compromising the integrity of the final product. The demand for precise building blocks like 2,3,5-Trimethylpyridine N-Oxide continues to grow as pharmaceutical companies strive for more efficient and targeted drug development.

For those seeking to buy 2,3,5-trimethylpyridine n-oxide, partnering with NINGBO INNO PHARMCHEM CO.,LTD. guarantees a source that understands the rigorous demands of the pharmaceutical industry. We facilitate the 2,3,5-trimethylpyridine n-oxide synthesis process by providing a dependable supply of this crucial compound. Our dedication to supporting scientific advancement means we are a steadfast partner in your journey from chemical synthesis to therapeutic breakthroughs.